MADISON, Wis., Feb. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2022 financial results after the close of the U.S. financial markets on February 21, 2023. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Fourth quarter 2022 webcast & conference call details
Date: | Tuesday, February 21, 2023 |
Time: | 5 p.m. ET |
Webcast: | The live webcast can be accessed at www.exactsciences.com |
Telephone: | Domestic callers, dial 888-330-2384 |
International callers, dial +1 240-789-2701 | |
Access code for both domestic and international callers: 4437608 |
An archive of the webcast will be available at www.exactsciences.com. A replay of the conference call will be available by calling 800-770-2030 domestically or +1 647-362-9199 internationally. The access code for the replay of the call is 4437608. The webcast, conference call, and replay are open to all interested parties.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard® and Oncotype® tests, Exact Sciences is investing in its product pipeline to support patients before and throughout their cancer diagnosis and treatment. Exact Sciences unites visionary collaborators to help advance the fight against cancer. For more information, please visit the company's website at www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.
Contact:
Megan Jones
Exact Sciences Corp.
This email address is being protected from spambots. You need JavaScript enabled to view it.
608-535-8815
| Last Trade: | US$54.75 |
| Daily Change: | -0.49 -0.89 |
| Daily Volume: | 1,365,311 |
| Market Cap: | US$10.130B |
January 21, 2025 January 21, 2025 January 12, 2025 November 25, 2024 November 13, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
